Fig. 2From: Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in BangladeshKaplan-Meier 30-day survival curve for high dose of baricitinib (blue line) and usual dose of baricitinib (green line). Analysis was ran using Group (HD/case vs UD/control) as factor; death as event and time to death as time variableBack to article page